Patrick Campbell

A study on a web app for nonprescription statin therapy shows high concordance with clinician assessment, with 84.5% of participants achieving LDL-C reduction of 20% or more.

José López, MD, discusses a case series from ACC.24 related to leadless pacemaker extraction and reimplantation.

Christie Ballantyne, MD, discusses new data from the ROSE2 trial examining the potential synergistic effects of obicetrapib with ezetimibe in high-intensity statin users.

Martin Maron, MD, discusses the results of the IMPROVE-HCM trial and how it informs the community on the potential of ninerafaxstat.

Christie Ballantyne, MD, discusses data from the SHASTA-2 trial and how it informs the community on the potential of plozasiran in management of severe hypertriglyceridemia.

Veraprapas Kittipibul, MD, discusses an analysis of the TRANSFORM-HF trial at ACC.24.

Muthiah Vaduganathan, MD, MPH, discusses a presentation from ACC.24 assessing the effects of dapagliflozin across a range of left ventricular hypertrophy from DELIVER.

REDUCE-AMI concluded beta-blockers show no significant benefit following myocardial infarction among patients with normal left ventricular ejection fraction

Alberto Foà, MD, PhD, discusses a PARAGON-HF analysis from ACC.24 examining treatment-related hypotension in people with HFmrEF/HFpEF.

Plozasiran demonstrates a 74% reduction in triglyceride levels at 24 weeks in patients with severe hypertriglyceridemia in the phase 2b SHASTA-2 trial.

Veraprapas Kittipibul, MD, discusses a study examining costs associated with heart failure hospitalization among patients with HFrEF or HFpEF from within the GWTG-HF registry.

The STEP HFpEF DM trial at ACC.24 shows significant improvements in symptoms among patients with obesity-related HFpEF and diabetes mellitus.

New data from a phase 3b trial presented at ACC.24 underlines the potential of inclisiran in reducing LDL-C levels among patients with ASCVD.

CSL112 infusion did not reduce major cardiovascular events at 90 days but further analysis suggests patients with elevated LDL-C levels could derive significant benefit.

Results of EMPACT-MI suggest use of empagliflozin was not associated with a statistically significant reduction in a composite of death and heart failure hospitalization.

In this endocrinology month in review for March 2024, we recap the most popular FDA news and pipeline updates as well as recognizing the 2-year anniversary of Diabetes Dialogue.

Less than 2 months after being the subject of an FDA AdComm meeting, Abbott's TriClip TEER System has received approval for tricuspid regurgitation.

A recap of the biggest FDA news and decisions in cardiovascular medicine from the first 3 months of 2024, with commentary on recent announcements by Deepak Bhatt, MD, MPH, MBA.

Verve Therapeutics announced plans to voluntary pause enrollment of the Heart-1 trial, citing an adverse event and consultation with DSMB, with plans to shift focus to VERVE-102 and Heart-2 trial.

The first-in-human trial of VRON-0200, a novel immunotherapy for chronic hepatitis B virus, presented at the APSAL meeting, demonstrates a promising safety and tolerability profile.

A REDUCE-IT analysis highlights consistent cardiovascular benefits with icosapent ethyl across varying levels of Lp(a).

The US FDA approval of sotatercept for PAH was announced by Merck on March 26, 2024.

Michael Weber, MD, lead of the PRECISION trial, discusses the significance of the aprocitentan (Tryvio) approval and key points for providers who may have patients with uncontrolled hypertension.

Presence of nephritis in SLE patients is linked to higher cardiovascular risk factors and 3-fold increase in incidence of cardiovascular mortality.

Implementing a Food as Medicine program improved diet, physical activity, and reduced cardiovascular risk factors among participants.

The FDA's approval of the label expansion for bempedoic acid to include cardiovascular risk reduction is based on data from the CLEAR Outcomes trial.

An analysis of 3 randomized clinical trials from the evinacumab program suggests the ANGPTL3 inhibitor was associated with reduced triglyceride-rich lipoprotein levels.

Idorsia Ltd. announced the FDA's approval of aprocitentan (Tryvio) for treatment-resistant hypertension on March 20, 2024.

An analysis of NHANES data suggests fewer than 3 in 10 patients with NAFLD received statin therapy, with only 50% with dyslipidemia receiving statins.